$831 Million is the total value of Ikarian Capital, LLC's 140 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ERYP | Exit | PHAXIAM THERAPEUTICS S Asponsored adr | $0 | – | -3,019 | -100.0% | 0.00% | – |
| MDGL | Exit | MADRIGAL PHARMACEUTICALS INC | $0 | – | -75 | -100.0% | -0.00% | – |
| SYBX | Exit | SYNLOGIC INC | $0 | – | -306,757 | -100.0% | -0.02% | – |
| KDNY | Exit | CHINOOK THERAPEUTICS INC | $0 | – | -283,464 | -100.0% | -0.02% | – |
| ASND | Exit | ASCENDIS PHARMA A/Ssponsored adr | $0 | – | -2,090 | -100.0% | -0.03% | – |
| CNTB | Exit | CONNECT BIOPHARMA HLDGS LTDads | $0 | – | -219,501 | -100.0% | -0.04% | – |
| PNT | Exit | POINT BIOPHARMA GLOBAL INC | $0 | – | -28,784 | -100.0% | -0.04% | – |
| ELDN | Exit | ELEDON PHARMACEUTICALS INC | $0 | – | -221,830 | -100.0% | -0.05% | – |
| MRSN | Exit | MERSANA THERAPEUTICS INCcall | $0 | – | -110,600 | -100.0% | -0.06% | – |
| RETA | Exit | REATA PHARMACEUTICALS INCcl a | $0 | – | -5,472 | -100.0% | -0.09% | – |
| XFOR | Exit | X4 PHARMACEUTICALS INC | $0 | – | -349,133 | -100.0% | -0.11% | – |
| ARDX | Exit | ARDELYX INC | $0 | – | -278,825 | -100.0% | -0.15% | – |
| PTGX | Exit | PROTAGONIST THERAPEUTICS INC | $0 | – | -35,000 | -100.0% | -0.15% | – |
| FGEN | Exit | FIBROGEN INCput | $0 | – | -379,300 | -100.0% | -0.16% | – |
| RPHM | Exit | RENEO PHARMACEUTICALS INC | $0 | – | -155,819 | -100.0% | -0.16% | – |
| FGEN | Exit | FIBROGEN INCcall | $0 | – | -400,000 | -100.0% | -0.17% | – |
| BLUE | Exit | BLUEBIRD BIO INC | $0 | – | -412,628 | -100.0% | -0.22% | – |
| MRUS | Exit | MERUS N V | $0 | – | -63,125 | -100.0% | -0.26% | – |
| LEGN | Exit | LEGEND BIOTECH CORPsponsored ads | $0 | – | -25,000 | -100.0% | -0.28% | – |
| QURE | Exit | UNIQURE NVcall | $0 | – | -154,400 | -100.0% | -0.28% | – |
| ICPT | Exit | INTERCEPT PHARMACEUTICALS IN | $0 | – | -160,200 | -100.0% | -0.28% | – |
| Exit | DICE THERAPEUTICS INCput | $0 | – | -43,600 | -100.0% | -0.32% | – | |
| ACRS | Exit | ACLARIS THERAPEUTICS INC | $0 | – | -200,163 | -100.0% | -0.33% | – |
| DCPH | Exit | DECIPHERA PHARMACEUTICALS IN | $0 | – | -174,510 | -100.0% | -0.39% | – |
| BBIO | Exit | BRIDGEBIO PHARMA INCput | $0 | – | -150,000 | -100.0% | -0.41% | – |
| ARWR | Exit | ARROWHEAD PHARMACEUTICALS IN | $0 | – | -130,000 | -100.0% | -0.74% | – |
| LEGN | Exit | LEGEND BIOTECH CORPcall | $0 | – | -68,800 | -100.0% | -0.76% | – |
| BCYC | Exit | BICYCLE THERAPEUTICS PLCsponsored ads | $0 | – | -203,037 | -100.0% | -0.82% | – |
| XENE | Exit | XENON PHARMACEUTICALS INC | $0 | – | -135,486 | -100.0% | -0.83% | – |
| Exit | BIOHAVEN LTDcall | $0 | – | -225,000 | -100.0% | -0.86% | – | |
| PTGX | Exit | PROTAGONIST THERAPEUTICS INCcall | $0 | – | -200,000 | -100.0% | -0.88% | – |
| PTGX | Exit | PROTAGONIST THERAPEUTICS INCput | $0 | – | -211,400 | -100.0% | -0.93% | – |
| BMEA | Exit | BIOMEA FUSION INC | $0 | – | -275,875 | -100.0% | -0.96% | – |
| BMEA | Exit | BIOMEA FUSION INCput | $0 | – | -286,700 | -100.0% | -1.00% | – |
| RETA | Exit | REATA PHARMACEUTICALS INCcall | $0 | – | -110,000 | -100.0% | -1.79% | – |
| MRK | Exit | MERCK & CO INC | $0 | – | -100,000 | -100.0% | -1.84% | – |
| APLS | Exit | APELLIS PHARMACEUTICALS INC | $0 | – | -133,800 | -100.0% | -1.94% | – |
| ARGX | Exit | ARGENX SEcall | $0 | – | -38,000 | -100.0% | -2.36% | – |
| AZN | Exit | ASTRAZENECA PLCcall | $0 | – | -250,000 | -100.0% | -2.85% | – |
| TGTX | Exit | TG THERAPEUTICS INCput | $0 | – | -826,100 | -100.0% | -3.27% | – |
| TGTX | Exit | TG THERAPEUTICS INCcall | $0 | – | -826,100 | -100.0% | -3.27% | – |
| BMEA | Exit | BIOMEA FUSION INCcall | $0 | – | -936,800 | -100.0% | -3.28% | – |
| ARGX | Exit | ARGENX SEput | $0 | – | -132,100 | -100.0% | -8.20% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 15 | Q2 2023 | 1.5% |
| OCULAR THERAPEUTIX INC | 15 | Q3 2023 | 1.4% |
| SAREPTA THERAPEUTICS INC | 14 | Q3 2023 | 6.4% |
| X4 PHARMACEUTICALS INC - PIPE | 14 | Q2 2023 | 1.4% |
| PROTARA THERAPEUTICS INC | 14 | Q3 2023 | 1.2% |
| SPDR SER TR | 13 | Q3 2023 | 9.0% |
| VAXCYTE INC | 13 | Q3 2023 | 2.9% |
| TRACON PHARMACEUTICALS INC | 13 | Q3 2023 | 1.4% |
| MILESTONE PHARMACEUTICALS IN | 13 | Q3 2023 | 1.7% |
| BELLUS HEALTH INC NEW | 13 | Q1 2023 | 1.8% |
View Ikarian Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Milestone Pharmaceuticals Inc. | February 14, 2023 | 460,416 | 1.3% |
| X4 Pharmaceuticals, Inc | February 14, 2023 | 349,133 | 0.3% |
| aTYR PHARMA INC | February 14, 2022 | 35,048 | 0.1% |
| Cyclacel Pharmaceuticals, Inc. | February 14, 2022 | 99,422 | 1.0% |
| KalVista Pharmaceuticals, Inc. | February 14, 2022 | 36,576 | 0.2% |
| Lyra Therapeutics, Inc. | February 14, 2022 | 394,536 | 3.0% |
| Odonate Therapeutics, Inc. | February 14, 2022 | 1,340,631 | 3.5% |
| Protara Therapeutics, Inc. | February 14, 2022 | 279,256 | 2.5% |
| Science 37 Holdings, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| scPharmaceuticals Inc. | February 14, 2022 | 901,362 | 3.3% |
View Ikarian Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
View Ikarian Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.